奧利司他 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "奧利司他" in Chinese language version.

Last modified: 08:48:59, 13 October 2026 (UTC)

Ref.Un. Ref.Website

Global rank Chinese rank

2321web.archive.org

1^st place

1412nih.gov

5^th place

3^rd place

88doi.org

2^nd place

5^th place

33archive.org

6^th place

2^nd place

31rocheusa.com

low place

22worldcat.org

4^th place

11kgh.com.tw

low place

11udn.com

474^th place

20^th place

11emedtv.com

low place

11legislation.gov.au

7,405^th place

6,915^th place

11usatoday.com

55^th place

147^th place

11info.gov.hk

1,611^th place

79^th place

11nhs.uk

2,637^th place

1,960^th place

11archive-it.org

1,292^nd place

922^nd place

11bu.edu

2,348^th place

3,001^st place

11scielo.br

1,374^th place

2,729^th place

11fda.gov

470^th place

386^th place

11ama-assn.org

4,430^th place

3,519^th place

11bmj.com

1,341^st place

926^th place

11nytimes.com

7^th place

21^st place

11nejm.org

2,717^th place

1,486^th place

11mhra.gov.uk

low place

11fda.gov.tw

low place

1,776^th place

11nmpa.gov.cn

low place

4,516^th place

11yaozh.com

low place

11huaxia.com

8,558^th place

453^rd place

11cctv.com

1,888^th place

86^th place

11ccfdie.org

low place

ama-assn.org (Global: 4,430^th place; Chinese: 3,519^th place)

archinte.ama-assn.org

存档副本. [2011-04-12]. （原始内容存档于2011-08-31）.

archive-it.org (Global: 1,292^nd place; Chinese: 922^nd place)

wayback.archive-it.org

FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter (PDF) (新闻稿). PRNewswire. 7 February 2007 [8 April 2007]. （原始内容 (PDF)存档于2007年8月24日）.

archive.org (Global: 6^th place; Chinese: 2^nd place)

Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995, 35 (11): 1103–8. PMID 8626884.
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999, 281 (3): 235–42. PMID 9918478. doi:10.1001/jama.281.3.235.
Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003, 43 (4): 428–35. PMID 12723464. doi:10.1177/0091270003252236.

bmj.com (Global: 1,341^st place; Chinese: 926^th place)

Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.

bu.edu (Global: 2,348^th place; Chinese: 3,001^st place)

bumc.bu.edu

FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter (PDF) (新闻稿). PRNewswire. 7 February 2007 [8 April 2007]. （原始内容 (PDF)存档于2007年8月24日）.

ccfdie.org (Global: low place; Chinese: low place)

国家食品药品监督管理局提醒关注奥利司他安全性问题-. www.ccfdie.org. [2025-04-10]. （原始内容存档于2025-04-30）.

cctv.com (Global: 1,888^th place; Chinese: 86^th place)

news.cctv.com

陈平丽. 非处方减肥药奥利司他能随意服用吗. news.cctv.com. [2025-04-10]. （原始内容存档于2025-04-30）.

doi.org (Global: 2^nd place; Chinese: 5^th place)

Barbier, Pierre; Schneider, Fernand. Syntheses of Tetrahydrolipstatin and Absolute Configuration of Tetrahydrolipstatin and Lipstatin. Helvetica Chimica Acta. 1987-02-04, 70 (1): 196–202. ISSN 0018-019X. doi:10.1002/hlca.19870700124.
Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）
Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999, 281 (3): 235–42. PMID 9918478. doi:10.1001/jama.281.3.235.
J. A. Menendez; L. Vellon; R. Lupu. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Annals of Oncology. 2005, 16 (8): 1253–1267. PMID 15870086. doi:10.1093/annonc/mdi239.
Garcia S, da Costa Barros L, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, de Oliveira Vespúcio M, Uyemura S. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006, 240 (2): 221–4. PMID 16377080. doi:10.1016/j.canlet.2005.09.011.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.
Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003, 43 (4): 428–35. PMID 12723464. doi:10.1177/0091270003252236.

emedtv.com (Global: low place; Chinese: low place)

weight-loss.emedtv.com

Orlistat side effects. [2018-04-12]. （原始内容存档于2020-08-01）.

fda.gov (Global: 470^th place; Chinese: 386^th place)

FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. fda.gov. [2018-04-13]. （原始内容存档于2019-04-24）.

fda.gov.tw (Global: low place; Chinese: 1,776^th place)

衛署藥輸字第025135號. [2018-04-12]. （原始内容存档于2019-08-15）.

huaxia.com (Global: 8,558^th place; Chinese: 453^rd place)

“减肥神药”竟成“中华老字号”，谁是背后推手？ - 社会综合 - 华夏经纬网. www.huaxia.com. [2025-04-10]. （原始内容存档于2025-04-30）.

info.gov.hk (Global: 1,611^th place; Chinese: 79^th place)

安全使用含奧利司他的藥物. [2010-05-29]. （原始内容存档于2019-09-02）.

kgh.com.tw (Global: low place; Chinese: low place)

漫談減肥和藥物治療. 郭綜合醫院藥劑科. [2010-06-25]. （原始内容存档于2020-02-18）.

legislation.gov.au (Global: 7,405^th place; Chinese: 6,915^th place)

POISON STANDARD JUNE 2017. [2018-04-12]. （原始内容存档于2020-12-13）.

mhra.gov.uk (Global: low place; Chinese: low place)

Orlistat: theoretical interaction with antiretroviral HIV medicines. MHRA. 13 March 2014 [16 November 2014]. （原始内容存档于2014-11-29）.

nejm.org (Global: 2,717^th place; Chinese: 1,486^th place)

Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.

nhs.uk (Global: 2,637^th place; Chinese: 1,960^th place)

Treating Obesity. NHS. [13 July 2013]. （原始内容存档于2017-10-13）.

nih.gov (Global: 5^th place; Chinese: 3^rd place)

ncbi.nlm.nih.gov

Zhi J, Melia AT, Eggers H, Joly R, Patel IH. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol. 1995, 35 (11): 1103–8. PMID 8626884.
{{Torgerson J, Hauptman J, Boldrin M, Sjöström L (2004). "XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients". Diabetes Care. 27 (1): 155–61. doi:10.2337/diacare.27.1.155.PMID 14693982}}
[Torgerson J, Hauptman J, Boldrin M, Sjöström L (2004). "XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients". Diabetes Care. 27 (1): 155–61. doi:10.2337/diacare.27.1.155. PMID 14693982.]
[Siebenhofer, A; Jeitler, K; Horvath, K; Berghold, A; Siering, U; Semlitsch, T (28 March 2013). "Long-term effects of weight-reducing drugs in hypertensive patients". The Cochrane Database of Systematic Reviews (3): CD007654. doi:10.1002/14651858.CD007654.pub3. PMID 23543553.]
Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）
Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.
Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999, 281 (3): 235–42. PMID 9918478. doi:10.1001/jama.281.3.235.
J. A. Menendez; L. Vellon; R. Lupu. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Annals of Oncology. 2005, 16 (8): 1253–1267. PMID 15870086. doi:10.1093/annonc/mdi239.
Garcia S, da Costa Barros L, Turatti A, Martinello F, Modiano P, Ribeiro-Silva A, de Oliveira Vespúcio M, Uyemura S. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett. 2006, 240 (2): 221–4. PMID 16377080. doi:10.1016/j.canlet.2005.09.011.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.
Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol. 2003, 43 (4): 428–35. PMID 12723464. doi:10.1177/0091270003252236.
Sjöström, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H. P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998-07-18, 352 (9123): 167–172 [2018-04-13]. ISSN 0140-6736. PMID 9683204. （原始内容存档于2019-08-13）.

nmpa.gov.cn (Global: low place; Chinese: 4,516^th place)

药品不良反应信息通报（第36期）警惕奥利司他可能引起严重肝损害的风险. 国家药品监督管理局. 2011-03-04 [2025-4-10] （中文）.

nytimes.com (Global: 7^th place; Chinese: 21^st place)

Kolata, Gina. Obesity Drug Can Lead to Modest Weight Loss, Study Finds. The New York Times. 20 January 1999 [11 December 2007]. （原始内容存档于2019-08-13）.

rocheusa.com (Global: low place; Chinese: low place)

Roche Pharmaceuticals. Xenical (PDF). Roche. July 2008 [19 February 2007]. （原始内容 (PDF)存档于2007-02-08）.

scielo.br (Global: 1,374^th place; Chinese: 2,729^th place)

Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）

udn.com (Global: 474^th place; Chinese: 20^th place)

免處方首例康孅伴減肥藥下月開賣. 聯合報. 2010-06-25 [2010-06-25]. （原始内容存档于2010-06-28）.

usatoday.com (Global: 55^th place; Chinese: 147^th place)

usatoday30.usatoday.com

"FDA OKs First Nonprescription Diet Pill. [2018-04-12]. （原始内容存档于2014-01-08）.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

漫談減肥和藥物治療. 郭綜合醫院藥劑科. [2010-06-25]. （原始内容存档于2020-02-18）.
免處方首例康孅伴減肥藥下月開賣. 聯合報. 2010-06-25 [2010-06-25]. （原始内容存档于2010-06-28）.
Orlistat side effects. [2018-04-12]. （原始内容存档于2020-08-01）.
POISON STANDARD JUNE 2017. [2018-04-12]. （原始内容存档于2020-12-13）.
"FDA OKs First Nonprescription Diet Pill. [2018-04-12]. （原始内容存档于2014-01-08）.
安全使用含奧利司他的藥物. [2010-05-29]. （原始内容存档于2019-09-02）.
Treating Obesity. NHS. [13 July 2013]. （原始内容存档于2017-10-13）.
Roche Pharmaceuticals. Xenical (PDF). Roche. July 2008 [19 February 2007]. （原始内容 (PDF)存档于2007-02-08）.
Mancini MC, Halpern A. Pharmacological treatment of obesity. Arq Bras Endocrinol Metab. 2006, 50 (2): 377–89. PMID 16767304. doi:10.1590/S0004-27302006000200024. Free full text with registration （页面存档备份，存于互联网档案馆）
FDA Drug Safety Communication: Completed safety review of Xenical/Alli (orlistat) and severe liver injury. fda.gov. [2018-04-13]. （原始内容存档于2019-04-24）.
存档副本. [2011-04-12]. （原始内容存档于2011-08-31）.
Douglas, Ian J; Julia Langham; Krishnan Bhaskaran; Ruth Brauer; Liam Smeeth. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ. 2013, 346: f1936 [2018-04-13]. PMC 3624963 . PMID 23585064. doi:10.1136/bmj.f1936. （原始内容存档于2021-01-16）.
Kolata, Gina. Obesity Drug Can Lead to Modest Weight Loss, Study Finds. The New York Times. 20 January 1999 [11 December 2007]. （原始内容存档于2019-08-13）.
Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer (PDF). N Engl J Med. 1998, 339 (18): 1277–84 [2018-04-13]. PMID 9791143. doi:10.1056/NEJM199810293391803. （原始内容存档于2018-04-13）.
Orlistat: theoretical interaction with antiretroviral HIV medicines. MHRA. 13 March 2014 [16 November 2014]. （原始内容存档于2014-11-29）.
衛署藥輸字第025135號. [2018-04-12]. （原始内容存档于2019-08-15）.
Sjöström, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H. P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998-07-18, 352 (9123): 167–172 [2018-04-13]. ISSN 0140-6736. PMID 9683204. （原始内容存档于2019-08-13）.
奥利司他市场调研分析_药智新闻. news.yaozh.com. [2025-04-10]. （原始内容存档于2025-04-30）.
“减肥神药”竟成“中华老字号”，谁是背后推手？ - 社会综合 - 华夏经纬网. www.huaxia.com. [2025-04-10]. （原始内容存档于2025-04-30）.
陈平丽. 非处方减肥药奥利司他能随意服用吗. news.cctv.com. [2025-04-10]. （原始内容存档于2025-04-30）.
国家食品药品监督管理局提醒关注奥利司他安全性问题-. www.ccfdie.org. [2025-04-10]. （原始内容存档于2025-04-30）.

worldcat.org (Global: 4^th place; Chinese: 4^th place)

Barbier, Pierre; Schneider, Fernand. Syntheses of Tetrahydrolipstatin and Absolute Configuration of Tetrahydrolipstatin and Lipstatin. Helvetica Chimica Acta. 1987-02-04, 70 (1): 196–202. ISSN 0018-019X. doi:10.1002/hlca.19870700124.
Sjöström, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H. P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet (London, England). 1998-07-18, 352 (9123): 167–172 [2018-04-13]. ISSN 0140-6736. PMID 9683204. （原始内容存档于2019-08-13）.

yaozh.com (Global: low place; Chinese: low place)

news.yaozh.com

奥利司他市场调研分析_药智新闻. news.yaozh.com. [2025-04-10]. （原始内容存档于2025-04-30）.

奧利司他 (Chinese Wikipedia)

ama-assn.org (Global: 4,430th place; Chinese: 3,519th place)

archinte.ama-assn.org

archive-it.org (Global: 1,292nd place; Chinese: 922nd place)

wayback.archive-it.org

archive.org (Global: 6th place; Chinese: 2nd place)

bmj.com (Global: 1,341st place; Chinese: 926th place)

bu.edu (Global: 2,348th place; Chinese: 3,001st place)

bumc.bu.edu

ccfdie.org (Global: low place; Chinese: low place)

cctv.com (Global: 1,888th place; Chinese: 86th place)

news.cctv.com

doi.org (Global: 2nd place; Chinese: 5th place)

emedtv.com (Global: low place; Chinese: low place)

weight-loss.emedtv.com

fda.gov (Global: 470th place; Chinese: 386th place)

fda.gov.tw (Global: low place; Chinese: 1,776th place)

huaxia.com (Global: 8,558th place; Chinese: 453rd place)

info.gov.hk (Global: 1,611th place; Chinese: 79th place)

kgh.com.tw (Global: low place; Chinese: low place)

legislation.gov.au (Global: 7,405th place; Chinese: 6,915th place)

mhra.gov.uk (Global: low place; Chinese: low place)

nejm.org (Global: 2,717th place; Chinese: 1,486th place)

nhs.uk (Global: 2,637th place; Chinese: 1,960th place)

nih.gov (Global: 5th place; Chinese: 3rd place)

ncbi.nlm.nih.gov

nmpa.gov.cn (Global: low place; Chinese: 4,516th place)

nytimes.com (Global: 7th place; Chinese: 21st place)

rocheusa.com (Global: low place; Chinese: low place)

scielo.br (Global: 1,374th place; Chinese: 2,729th place)

udn.com (Global: 474th place; Chinese: 20th place)

usatoday.com (Global: 55th place; Chinese: 147th place)

usatoday30.usatoday.com

web.archive.org (Global: 1st place; Chinese: 1st place)

worldcat.org (Global: 4th place; Chinese: 4th place)

yaozh.com (Global: low place; Chinese: low place)

news.yaozh.com

ama-assn.org (Global: 4,430^th place; Chinese: 3,519^th place)

archive-it.org (Global: 1,292^nd place; Chinese: 922^nd place)

archive.org (Global: 6^th place; Chinese: 2^nd place)

bmj.com (Global: 1,341^st place; Chinese: 926^th place)

bu.edu (Global: 2,348^th place; Chinese: 3,001^st place)

cctv.com (Global: 1,888^th place; Chinese: 86^th place)

doi.org (Global: 2^nd place; Chinese: 5^th place)

fda.gov (Global: 470^th place; Chinese: 386^th place)

fda.gov.tw (Global: low place; Chinese: 1,776^th place)

huaxia.com (Global: 8,558^th place; Chinese: 453^rd place)

info.gov.hk (Global: 1,611^th place; Chinese: 79^th place)

legislation.gov.au (Global: 7,405^th place; Chinese: 6,915^th place)

nejm.org (Global: 2,717^th place; Chinese: 1,486^th place)

nhs.uk (Global: 2,637^th place; Chinese: 1,960^th place)

nih.gov (Global: 5^th place; Chinese: 3^rd place)

nmpa.gov.cn (Global: low place; Chinese: 4,516^th place)

nytimes.com (Global: 7^th place; Chinese: 21^st place)

scielo.br (Global: 1,374^th place; Chinese: 2,729^th place)

udn.com (Global: 474^th place; Chinese: 20^th place)

usatoday.com (Global: 55^th place; Chinese: 147^th place)

web.archive.org (Global: 1^st place; Chinese: 1^st place)

worldcat.org (Global: 4^th place; Chinese: 4^th place)